Med. Pro Praxi 2006; 2: 62-67

Mukolytika - léky nejen proti kašli

prof. MUDr. Vítězslav Kolek DrSc
Klinika plicních nemocí a tuberkulózy, FN a LF UP Olomouc

Práce se zabývá současným postavením různých skupin mukolytik v léčbě respiračních zánětů. Mukolytika lze rozdělit na léky potencující efekt surfaktantu (deriváty bromhexinu), thiolové látky štěpící SH skupiny mucinů a enzymatické působky. Kromě ovlivnění reologie hlenu jsou uvedeny základní účinky, jako je antioxidační, protizánětlivý a antibakteriální efekt. Práce zdůrazňuje současný význam mukolytik dle platných klinických doporučení léčby chronické obstrukční nemoci (CHOPN). Jsou komentovány nové multicentrické studie, které přinesly další zajímavé informace o ovlivnění CHOPN ve vztahu k počtu exacerbací, trvání symptomů a zlepšení plicních funkcí. Je hodnocen také vliv na kvalitu života a ekonomický dopad léčby. Práce zdůrazňuje pohled na mukolytika prismatem medicíny podložené důkazy.

Keywords: mukolytika, oxidační stres, respirační záněty, chronická obstrukční plicní nemoc

Published: September 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kolek V. Mukolytika - léky nejen proti kašli. Med. praxi. 2006;3(2):62-67.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aruoma OI, Halliwell B, Hoey BM. The antioxidant action of N-acetylcysteine: Its reaction with hydrogen peroxide, hydroxyl radical, superoxide and hypochlorous acid. Free Rad. Biol. Mes., 1989; 6: 593. Go to original source... Go to PubMed...
    2. Braga PC, Dal Sasso M, Sala MT, et al. Effects of erdosteine and its metabolites on bacterial adhesiveness. Arzneimittel Forschung Drug Research, 1999; 494: 344-349.
    3. Biagi GL, Fregnan GB, Gazzani G. Erdosteine protection from cigarette smoke-induced loss of ?-1-antitrypsin activity in rat lungs. Int. J. Clin. Pharmacol. Ther. Toxicol. 1989; 27: 235-237.
    4. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J., 2003; 22: 912-919. Go to original source... Go to PubMed...
    5. Celli BR, MacNee W, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J., 2004; 23: 932-946. Go to original source... Go to PubMed...
    6. Ciaccia A, Papi A, Tschirky B, et al. Protection of erdosteine on smoke-induced peripheral neutrophil dysfunction both in healthy and in bronchitic smokers. Fundam. Clin. Pharmacol., 1992; 6: 375-379. Go to original source... Go to PubMed...
    7. Decramer M, Rutten-van Mölken M, Dekherijeen PNR, et al. Effect of N-acetylcystein on outcomes in chronic obstrutive pulmonary disease (Bronchitis Randomized on N-acetylcystein CostUtility Study, BRONCUS): a randomised placebo-controlled trial. Lancet, 2005; 365: 1552-1560. Go to original source... Go to PubMed...
    8. Dal Sasso M, Bovio C, Culici M, et al. The SH-metabolite I of erdostein, a mucolytic drug, enhances the inhibitory effect of salbutamol on the respiratory burst of neutrophils. Drugs. Exp. Clin. 2002; 28: 147-154.
    9. Dal Sasso M, Culici M, Guffanti EE, et al. A combination of budenoside and the SH-metabolite I of erdostein acts synergistically in reducing chemiluminiscence dutiny human neutrophil respiratory burst. Pharmacol., 2005; 74: 127-134. Go to original source... Go to PubMed...
    10. Dal Negro RW, Visconti M, Micheletto C, et al. Erdostein 900 mg/day affects substancially blood ROS,e-NO and some chemotactic cytokines from bronchial secretions of current smokers. A pilot study. ATS 2005 Abstr. Book.
    11. Donnini M, Luisetti M, Diomede L, et al. Ambroxol reduces paraguat toxicity in the rat. In: Wichert P, von Muller B, eds. Basic Research on Lung Surfactant Progress in Respiratory Research. Karger, Basel,1990; 329-332. Go to original source...
    12. Fioretti M, Bandiera M. Prevention of exacerbations in chronic bronchitic patients with erdosteine. Med. Praxis., 1991; 12: 219-222.
    13. Gene R, et al. Influence of ambroxol on amoxicillin levels in broncho-alveolar lavage fluid. Arzneim.-Forsch./Drug. Res., 1987; 37: 967-968.
    14. Gerrits CMJM, Herings RMC, Leufkens HGM, et al. N-acetylcysteine reduces the risk of rehospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J., 2003; 21: 795-798. Go to original source... Go to PubMed...
    15. Grande JM, Snell NJ. Activity of bromhexine and ambroxol semi-synthetic derivatives of vasicine from the Indian shrub Adhatoda vasica against Mycobacterium tuberculosis in vitro. J. Ethopharmacol, 1996; 50: 49-53. Go to original source...
    16. Grandjean EM, Berthet P, Ruffman R, et al. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A meta-analysis of published double-blind, placebo-controlled clinical trials. Clin. Ther., 2000; 22: 209-212. Go to original source... Go to PubMed...
    17. Hayashi K, Hosoe H, Kaise T. Protective effect of erdosteine against hypochlorous acid-induced acute lung injury and lipopolysaccharide-induced neutrophilic lung inflammation in mice. J. Pharm. Pharmacol., 2000; 52: 1411-1413. Go to original source... Go to PubMed...
    18. Hosoe H, Kaise T, Ohmori K. Effects on the Reactive Oxygen Species of Erdosteine and its Metabolite in vitro. Arzneim.-Forsch. Drug Res., 2002; 52: 435-440. Go to original source...
    19. Irwin RS, Curley FL, Bennett FM. Appropriate use of antitussives and protussives: a practical review. Drugs. 1993; 46: 80-91. Go to original source... Go to PubMed...
    20. Kastelik JA, Aziz I, Ojoo JC, et al. Investigation and management of chronic cough using a probability-based algorithm. Eur Respir J., 2005; 25: 235-243. Go to original source... Go to PubMed...
    21. Kolek V, Engel G. Ambroxol : Známá látka s novým spektrem klinického využití. Zpravodaj klinické farmakologie a farmacie, 1997; 11: 25-29.
    22. Kolek V. Chronický kašel. Příčiny, diagnostika, léčba. Praha, Vltavín, 2002; 72 s.
    23. Marchioni CF, Moretii M, Muratory M, et al. Effects of erdosteine on sputum biochemical and rheologic properties: Pharmacokinetics in chronic obstructive pulmonary disease. Lung, 1990; 68: 285-293. Go to original source... Go to PubMed...
    24. Marchioni CF, Polu JM, Taytard A, Hanard T, Noseda G, and Mancini C. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Int. J. Clin. Pharm. and Therap., 1995; 33: 612-618.
    25. Moretti M, Bottrighi P, Falladi R, et al. The effect of long-term treatment with erdostein on chronic obstructive pulmonary disease: The EQALIFE study. Drugs Explt.Clin. Res. 2004; 30: 143-152.
    26. Miyake K, Kaise T, Hosoe H. The effect of erdosteine and its active metabolite on reactive oxygen species production by inflammatory cells. Inflammation Res., 1999; 48: 205-210. Go to original source... Go to PubMed...
    27. National Institute for Clinical Excellence (NICE). Chronic obstructive pulmonary disease: national clinical quideline for management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax, 2004; 59 (Suppl I).
    28. Olivieri D, Del Donno M, Vasalini A, et al. Activity of erdosteine on mucociliary transport in patients affected by chronic bronchitis. Respiration, 1991; 58: 91-94. Go to original source... Go to PubMed...
    29. Poole PJ, Black PN. Mucolytic for chronic bronchitis or chronic obstructive pulmonary disease (Cochrane Methodology Review). In: The Cochrane Library, Issue 4, John Wiley&Sons, Ltd., Chichester, 2003; 121-130. Go to original source...
    30. Repine JE, Bast A, Lankhorst I. and the Oxidative Stress Study Group: Oxidative stress in COPD. Am. J. Respir. Crit. Care Med., 1997; 156: 341-357. Go to original source... Go to PubMed...
    31. Rubin BK. An In Vitro Comparison of the Mucoactive Properties of Guaifenesin, Iodinated Glycerol, Surfactant, and Albuterol. CHEST, 1999; 116: 195-200. Go to original source... Go to PubMed...
    32. Stey C, Steurer J, Bachmann S. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J, 2000; 16: 253-262. Go to original source... Go to PubMed...
    33. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management chronic obstructive pulmonary disease. Eur. Respir. J., 2003; 21: 74-81. Go to original source... Go to PubMed...
    34. Vagliasindi M, Fregnan GB. Erdosteine protection against cigarette smoking-induced functional antiprotease deficiency in human bronchiolo-alveolar structures. Int. J. Clin. Pharmacol. Ther. Toxicol., 1989; 27: 238-241.
    35. www.goldcopd.com: Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.
    36. Zanasi A, Menadini A. Erdostein versus N-acetylcystein in the treatment of exacerbation of chronic bronchopneumopathies. Med. Praxis 1991; 12: 207-217.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.